Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

BACKGROUND & AIMS: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential associations between b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751218/
https://www.ncbi.nlm.nih.gov/pubmed/32710922
http://dx.doi.org/10.1016/j.jhep.2020.07.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751218/
https://www.ncbi.nlm.nih.gov/pubmed/32710922
http://dx.doi.org/10.1016/j.jhep.2020.07.026

Ejemplares similares